头孢洛扎-他唑巴坦对ASPECT-cIAI研究中鉴定出的厌氧生物的体外活性
In Vitro Activity of Ceftolozane-Tazobactam against Anaerobic Organisms Identified during the ASPECT-cIAI Study.
作者信息
Armstrong Eliana S, Farrell David J, Palchak Melissa, Steenbergen Judith N
机构信息
Merck & Co., Inc., Kenilworth, New Jersey, USA
JMI Laboratories, North Liberty, Iowa, USA.
出版信息
Antimicrob Agents Chemother. 2015 Nov 9;60(1):666-8. doi: 10.1128/AAC.01964-15. Print 2016 Jan.
The in vitro activities of ceftolozane-tazobactam, meropenem, and metronidazole were determined against anaerobic organisms isolated from patients with complicated intraabdominal infections (cIAI) in global phase III studies. Ceftolozane-tazobactam activity was highly variable among different species of the Bacteroides fragilis group, with MIC90 values ranging from 2 to 64 μg/ml. More-potent in vitro activity was observed against selected Gram-positive anaerobic organisms; however, small numbers of isolates were available, and, therefore, the clinical significance of these results is unknown. Variable activity of ceftolozane-tazobactam against anaerobic organisms necessitates use in combination with metronidazole for the treatment of cIAI.
在全球III期研究中，测定了头孢洛扎/他唑巴坦、美罗培南和甲硝唑对从复杂性腹腔内感染（cIAI）患者中分离出的厌氧生物的体外活性。头孢洛扎/他唑巴坦对脆弱拟杆菌群不同菌种的活性差异很大，MIC90值在2至64μg/ml之间。观察到对选定的革兰氏阳性厌氧生物有更强的体外活性；然而，分离株数量较少，因此这些结果的临床意义尚不清楚。头孢洛扎/他唑巴坦对厌氧生物的活性存在差异，因此需要与甲硝唑联合使用来治疗cIAI。
Zotero 插件